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The aim of the study is to assess sex difference in association between type 2 diabetes and incidence of major cardiovascular events,
that is, myocardial infarction, stroke, and heart failure, using information retrieved by diabetes register. The inhabitants of Reggio
Emilia (Italy) aged 30–84 were followed during 2012–2014. Incidence rate ratios and 95% confidence intervals were calculated using
multivariate Poisson model. The age- and sex-specific event rates were graphed. Subjects with type 2 diabetes had an excess risk
compared to their counterparts without diabetes for all the three major cardiovascular events. The excess risk is similar in
women and men for stroke (1.8 times) and heart failure (2.7 times), while for myocardial infarction, the excess risk in women is
greater than the one observed in men (IRR 2.58, 95% CI 2.22–3.00 and IRR 1.78, 95% CI 1.60–2.00, resp.; P of interaction < 0 0001).
Women had always a lesser risk than men, but in case of myocardial infarction, the women with type 2 diabetes lost part of
advantage gained by women free of diabetes (IRR 0.61, 95% CI 0.53–0.72 and IRR 0.36, 95% CI 0.33–0.39, resp.). In women with
type 2 diabetes, the risk of major cardiovascular events is anticipated by 20–30 years, while in men it is by 15–20.
1. Introduction
In the list of the top ten killers created by the Global
Burden of Disease study, ischemic heart disease and stroke
contended for first place, causing 13% and 12% of the total
deaths in 2012, respectively. Moreover, the WHO estimated
that ischemic heart disease contributed to a third of the
96.4% increase in the prevalence of heart failure (HF) from
1990 to 2013 worldwide [1].
Accordingly, the European Society of Cardiology (ESC)
identifies cardiovascular diseases (CVDs) as the leading cause
of death in Europe. In a recent issue, the ESC estimated that,
despite recent decreases in mortality rate in many countries,
close to half deaths in Europe in 2014 are attributable to
CVDs, with a higher proportion in women (51%) than in
men (42%) [2].
The WHO also identified diabetes as the fifth and ninth
cause of deaths in women and men, respectively [1]. Indeed,
diabetes is a major public health issue with an increasing
prevalenceglobally,affectingat least8%oftheadultpopulation
worldwide [3].
Cardiovascular diseases, including coronary heart disease
(CHD), stroke, and heart failure, are predominant causes of
morbidity and mortality among people with diabetes [4].
Conversely, diabetes increases the prevalence of most of
the main risk factors for CVDs, leading to an increased risk
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of related morbidity andmortality [5–12]. However, accruing
evidence highlights that women and men experience the
disease differently [13, 14]. Actually, women lose their relative
protection fromCVDs, and postmenopausal diabetic females,
compared to the general population, presented a stronger
increase of cardiometabolic risk than diabetic males, but the
reasons are not entirely clear [15–18]. The explanations are
likely to bemultifactorial, with contributions from differences
in inherent physiological factors and in the management
and treatment of diabetes, to the detriment of women [19, 20].
The data collected by the Italian Society of Diabetologists
(AMD) on quality of diabetes care and gender difference in
access to effective care in Italy, show, in a large population
of type 2 diabetes, that gender disparities in control of the dis-
ease are less pronounced in Italy than in other countries, but
they still exist, despite equity of access to specialist care and
the same pharmacological treatment of women andmen [21].
A specific negative interaction between being a woman
and having diabetes in CVDs risk was supported by most
of the studies [22–25] but questioned by some other
authors [18, 26]. The inconsistency of evidence could be
partly due to several limitations such as failure to distinguish-
ing between types of diabetes or selection bias in observational
studies or extremely selected populations in trial partici-
pants [27, 28]. Large register-based studies which identify
the different types of diabetes are required to examine differ-
ences between sex in CVD occurrence and mortality in the
general population.
In the Reggio Emilia province, the Diabetes Register
(REDR) was set up since 2009 and is able to ascertain cases
and to distinguish the type of diabetes [29].
The present study aims to assess sex differences in
the association between type 2 diabetes (T2D) and inci-
dence of major cardiovascular diseases (CVDs), that is,
myocardial infarction, stroke, and heart failure, using the
REDR information.
2. Materials and Methods
2.1. Setting and Study Population. This is a cohort study
where all residents in the Reggio Emilia province, Italy, as
of December 31st, 2011 (approx. 0.5 million inhabitants),
aged 30–84, were followed during 2012–2014 period. The
follow-up lasted until the date of first CVD event, all-causes
death, emigration, or end of follow-up (as of December
31st, 2014), whichever occurred first.
The residence and vital status information was retrieved
from the civil register, as well as T2D status from the Reggio
Emilia Diabetes Register (REDR).
The REDR is a validated database created by the
deterministic linkage of six routinely collected data sources
through a definite algorithm able to ascertain cases and to
distinguish type of diabetes and model of care [29]. Data have
been included since 2009, and the REDR is updated annually.
The date of inclusion in the register is the date when a person
first meets one of the following inclusion criteria: (1) disease-
specific exemption database: exemption from copayment due
to diabetes; (2) hospital discharge database: hospitalization
with diabetes diagnosis in whichever position by ICD-9
(InternationalClassificationofDiseasesClinicalModification,
9th Edition) codes 250.xx, 357.2x, 362.0x, 366.41, and 648.0x,
excluding MDC14; (3) biochemistry laboratory database: one
glycated haemoglobin (HbA1c) test ≥ 6 5% (48mmol/mol);
(4) drug prescription databases: redeemed prescription at
least twice for antidiabetic drugs in case of pharmacy distri-
bution, only one in case of direct distribution; (5) diabetes
outpatient clinics database: diagnosis by a diabetologist; and
(6) Reggio Emilia mortality register: cause of death by ICD-10
(International Classification of Diseases, 10th Edition) codes
E10–E14.Women with gestational diabetes or women receiv-
ing treatment for polycystic ovarian syndromewere excluded.
The type of diabetes, suggested by the presence of defined
criteria as described elsewhere [29], was confirmed by a diag-
nosis provided by a diabetologist or another physician.
Subjects included in the register with type 1 diabetes or
secondary diabetes (i.e., drug-induced diabetes, diseases of
exocrine pancreas, etc.) or with undefined diabetes were
excluded from the analysis.
2.2. Outcomes and Other Variables. The outcomes were the
first event between hospitalization and death for stroke,
myocardial infarction, and heart failure. Fatal events were
considered cases in which only the death certificate was pres-
ent or caseswith hospitalization followed by a death certificate
for the same cause during the study period. The outcomes
were defined according to the International Classification of
Disease, 9th Revision (ICD-9) in case of nonfatal event and
10th Revision (ICD-10) in case of fatal event: (1) nonfatal
stroke (ICD-9 codes 430–434) or death from cerebrovascular
disease (ICD-10 codes I60–I63); (2) nonfatal myocardial
infarction (ICD-9 codes 410‐411) or deaths from myocardial
infarction (ICD-10 codes I21, I22, I24.8, I24.9); and (3) heart
failure requiring hospitalization (ICD-9 code 428) or causing
death (ICD-10 code I50).
Data were retrieved from hospital discharge database in
case of nonfatal events, using primary diagnosis and exclud-
ing day hospital, and from Reggio Emilia mortality register
for deaths. Each participant could contribute only once to
incidence of each event, that is, with first event detected in
the study period, but the same subject could contribute for
more types of outcome.
Individual demographic information included age, sex,
and foreign status (i.e., non-Italian citizenship).
2.3. StatisticalMethods.The characteristics of the study popu-
lation are presented as median and proportions and stratified
by sex and T2D status. The event numbers and person-time
at risk were calculated for each major CVD examined.
Age-adjusted event rates (AAER) per 10,000 with 95%
confidence intervals (95% CI) by sex and T2D status for each
type of event were estimated using the Italian population as
of December 31st, 2011, as a reference for standardization
[30]. Incidence rate ratios (IRR) and 95% confidence intervals
(95% CI) for the risk of each CDV in people with T2D versus
the population without diabetes were calculated using mul-
tivariate Poisson regression models and stratifying by sex.
The effect modification of sex on the association between
T2D and CVDs was tested using the Wald test. Finally,
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the age-specific event rates stratified by sex for individuals
with and without diabetes were graphed.
The analyses were performed using the STATA statistical
package Version 13.0.
3. Results
On December 31st, 2011, the REDR included 14,531 and
12,424 prevalent men and women with T2D, respectively.
The overall prevalence is 5.7%and4.7%, respectively. Restrict-
ing to people aged 30–84, 13,714men and10,634women (44%
out of the total) with T2D were included in our study
(Table 1). The median age of the diabetic population is about
20 years higher than the people without diabetes.
During the 3-year follow-up, the number of fatal events
was higher for myocardial infarction than for other CVDs
(Table 2) (9.6% and 9.1% for men and women, resp., with
no difference between the two sexes). Among men without
T2D, myocardial infarction was the most frequent CVD,
closely followed by stroke and remotely by heart failure, while
amongwomenwithout T2D, the stroke was themost frequent
CVD, followed by myocardial infarction and heart failure,
both halved with respect to the former.
Performing the analysis without sex stratifications, the
stroke and myocardial infarction risks in people with T2D
were almost twofold higher than in those without diabetes,
while heart failure risk was almost three times higher (IRR
1.84, 95% CI 1.70–1.98; IRR 2.00, 95% CI 1.83–2.18; IRR
2.70, 95% CI 2.47–2.94, resp., data not reported in the tables).
Women with T2D had 1.8 times the probability of a stroke
(Table 2) than the women without diabetes (95% CI 1.61–
2.04), 2.6 times the probability of having a myocardial infarc-
tion and heart failure (95% CI 2.22–3.00 and 2.27–2.97, resp.).
Men with T2D have similar excess risk for stroke and heart
failure, but the excess risk for myocardial infarction is lower
than the one observed in women (IRR 1.78, 95%CI 1.60–2.00).
The relative risk for myocardial infarction associated
with T2D was significantly greater in women than in men
(P < 0 0001), while there is no evidence of sex difference for
the stroke and heart failure (P = 0 9151 andP = 0 9289, resp.).
Women free of diabetes had lesser risk than men free of
diabetes to experience whichever CVD events (Table 3).
The reduction is 30% in case of stroke and heart failure and
60% in case of myocardial infarction. Women with type 2
diabetes had also lesser risk than men with type 2 diabetes
to experience whichever CVD events, but in case of stroke
and heart failure, the reduction percentages were similar to
those found comparing sex free of diabetes; meanwhile, in
case of myocardial infarction, the reduction is only 30%
(instead of 60%).
The foreigners seemed to have similar risk of stroke
(in people with T2D IRR 0.93, 95% CI 0.62–1.40; in people
without T2D IRR 0.90, 95% CI 0.72–1.12) and heart failure
(in people with T2D IRR 0.76, 95% CI 0.45–1.28; in people
without T2D IRR 0.98, 95% CI 0.69–1.40), while in case of
myocardial infarction, a protective effect was found in
the population without T2D, but not in those with T2D
(in people with T2D IRR 1.03, 95% CI 0.71–1.48; in people
without T2D IRR 0.68, 95% CI 0.54–0.86). The same pattern
was observed in men and women.
In the women without diabetes, the risk is virtually zero
until 54 yrs for myocardial infarction, until 60 for stroke and
until 70 for heart failure (Figure 1; Annex 1 in Supplementary
Material available online at https://doi.org/10.1155/2017/
6039356), while for the men without diabetes, the risk is
appreciable from the age of 45 for myocardial infarction,
50 for stroke, and 65 for heart failure. In general, the risk
of CVD events in men and women with T2D starts to be
noticeable at an earlier age than in the population without
diabetes. The anticipation is longer in women than in men
for myocardial infarction and stroke. The resulting excess
risk for people with T2D is therefore higher in younger ages
for all the outcomes in both sexes and, particularly, for
myocardial infarction in women.
4. Discussion
In our study, people with T2D experienced an excess risk
for all the investigated CVDs, that is, stroke, myocardial
infarction, and heart failure. These results are consistent
with many studies [13, 14] and reflect those observed for
mortality in a previous analysis applied to the same popula-
tion, where we found an excess risk for cardiovascular
diseases in population with diabetes of both sexes, stronger
in women and in particular for myocardial infarction [31].
Although we observed nondiabetic women having fewer
CVD events than nondiabetic men of the same age, this
advantage appears to be partially lost for myocardial infarc-
tion in the context of T2D, but not for the other two CVDs.
Our results were consistent with those of a recent Italian
study that showed a diabetes-related excess risk greater in
women than in men for myocardial infarction but not for
heart failure and stroke [32].
In a Finnish cohort study [13], the presence of diabetes
reduced the so-called female advantage for CVD risk; indeed,
mortality from CHD was three times higher in women
compared with men with diabetes. Similar findings were
Table 1: Baseline characteristics of the study cohorts, age 30–84, Reggio Emilia—Italy, as of December 31st, 2011.
Men Women
Without T2DM With T2DM Without T2DM With T2DM
Inhabitants
Total, n 161,045 13,714 170,798 10,634
Foreigners, n (%) 17,444 (10.8) 907 (6.6) 19,336 (11.3) 846 (8.0)
Age (years): median (IQR) 48 (39–61) 67 (58–74) 50 (40–64) 70 (61–77)
T2D = type 2 diabetes.
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Figure 1: Age-specific event rates by sex, type 2 diabetes status, and type of event.
Table 3: Incidence rate ratios (IRR) with 95% confidence intervals (95% CI) by type 2 diabetes status and type of event, women versus men.
Women versus men
Without T2DM With T2DM
IRR 95% CI IRR 95% CI
Stroke 0.68 0.63–0.74 0.72 0.62–0.82
Myocardial infarction 0.36 0.33–0.39 0.61 0.53–0.72
Heart failure 0.63 0.57–0.69 0.66 0.58–0.77
IRR = calculated using Poisson model, adjusted for age and foreign status. Men were used as reference.
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observed in the NHANES cohort [33] and in the study based
on UK General Practice data [34], the latter investigating
subsequent myocardial infarction. The stronger impact of
diabetes as a major risk factor for CVD events in women
than men, 4.3-fold risk compared to 2.7, is described also in
the INTERHEART, an international case-control study
including 15,152 cases and 14,820 controls from 52 countries
[35]. On the other hand, a systematic review showed that the
risk of incident CHD was three times higher in women with
diabetes than in women without diabetes, while the risk in
men doubled [36]. A similar difference in the excess of risk,
50% more, was found in a previous systematic review [15].
We observed a risk of heart failure almost 3 times higher
in the presence of T2D, similar to results found in Oregon
[10] and in Iceland [37], but in our study, the overall excess
risk was similar in women and men (P = 0 9245). In the
Framingham Heart Study [25], the heart failure risk was 2
times higher in men and 5 times higher in women with
diabetes compared with the general population.
Also, in case of stroke, we found an excess risk for T2D
but no sex difference in the excess (P = 0 9197). The results
of individual studies on the sex differences on the risk of
stroke associated with diabetes have been inconsistent,
with some studies showing women with diabetes had
higher [13, 25, 38, 39], similar [40], or lower risk [41, 42]
compared to men with diabetes. In a recent comprehensive
systematic review and meta-analysis using data from 64
cohorts [20], the pooled analysis shows a significantly higher
relative effect of diabetes on stroke risk in women compared
to men, even adjusting for other major cardiovascular risk
factors. As suggested by other authors [32], the different prev-
alence of medical condition underlying the physiopathology
of stroke (i.e., arterial hypertension and atrial fibrillation)
between sexes [43] may reduce the difference in the gender-
related diabetes risk for stroke and myocardial infarction.
This greater excess coronary risk may be explained by
more adverse cardiovascular risk profiles among women with
diabetes, combined with possible disparities in treatment and
quality of care that favor men. A recent review explored
biological and environmental factors that play a role in the
reduction of the protective effect of female sex from CVD
in diabetic women [44]. The authors pointed out the inter-
action between insulin and the estrogen signaling and the
effect of hyperglycemia on the expression and activity of
estrogen receptors as mechanisms underlying the diabetes-
related impairment of endothelium in diabetic women. The
resulting proinflammatory environment accelerates the ath-
erosclerotic process that leads to coronary arteries disease,
particularly in women.
In two large population studies carried out in Italy [21, 45],
subjects with T2D—included the majority of the population
enrolled our study—were investigated to ascertain whether
gender differences in quality of care of diabetes exist in
Italy [21]. The authors found that the likelihood to reach
specific clinical outcomes is systematically unfavorable for
women as compared with men, although the disparities are
less pronounced than in other countries.
Many international studies documented a systematic
undertreatment of cardiovascular risk factors in diabetic
women: the results of the DIANA study [46] indicated that
men with diabetes were significantly more likely to receive
any treatment for the major CVD risk factors, including oral
hypoglycemic agents, ACE inhibitors, and calcium channel
blockers for CHD, than women. Evidence has emerged
demonstrating a potential sex disparity in the intensity of
cardiovascular risk reduction, whereby worse glycated hemo-
globin control, lower frequency of lipid-lowering therapy,
lower aspirin use, and lower blood pressure control were
noted in women [47].
In contrast with these international data [48], women
with diabetes in Italy are not undertreated with medications
for cardiovascular risk factors. Also in the study of Rossi
et al. [21], the proportion of diabetic women treated with
insulin, statins, or antihypertensive agents was equal to or
even higher than that of men. The MIND-IT (Multifactorial
Intervention in Type 2 Diabetes in Italy)—a cross-sectional
study that enrolled over 2,000 type 2 diabetic patients with-
out previous described CVD events—investigated the degree
of control of CVD risk factors [49]: diabetic women showed a
worse CVD risk profile, with a less percentage of diabetic
women reaching the recommended metabolic targets com-
pared to men, regardless of use of medications for CVD risk
factors control. In the light of reported evidence, we suggest
that both the diverse physiopathology and the systematic
use of ACE inhibitors or B-blockers and statins in Italian
diabetic patients, without gender differences, might explain
the lack of differences in stroke and heart failure risk between
men and women.
The age curves of risk show that in the population with
T2D the incidence is brought forward by 20–30 years in
women and by 15–20 years in men for stroke and myocardial
infarction, while for the heart failure, a marked anticipation
of the onset can be observed for both sexes (Figure 1; Annex 1
in Supplementary Material). Consequently, the incidence of
stroke and myocardial infarction in young ages is several
times higher than the one in the population without diabetes,
while in people over 70, it is only 2- or 1.5-fold. This is
particularly true for women, because the incidence of stroke
and myocardial infarction in the population without diabetes
remains virtually null before the age of 60. The results are
consistent with a previous study [13] in Finland.
4.1. Strengths and Limitation. The population-based cohort
study approach increases the external validity, and the use
of diabetes register reduces the ascertainment bias. Indeed,
the study excludes cases of type 1 diabetes (732), secondary
diabetes (137), or undefined diabetes (901), maximizing the
accuracy in the definition of the two subcohorts (i.e., with
and without T2D).
Although the AHA statement notes possible sex differ-
ences in cardiovascular outcomes within racial/ethnic groups,
our study did not have sufficient power to analyze differences
by geographical origin, although we use this covariate in mul-
tivariate model. In addition, we could not control for other
cardiovascular risk factors in the analysis, because unlike
observational studies of patients from clinical databases, there
is only limited clinical information on the general population;
hence, it is not possible to provide a detailed clinical
6 International Journal of Endocrinology
characterization of the general population. We foresee a sec-
ond study to investigate the determinants of CVD events only
in population with T2D using different clinical information
as well as prescribed drug and information on other areas
of care such as tests and lifestyle factors and diabetes
duration.
5. Conclusions
Women with T2D have earlier risk of major cardiovascular
events by 20–30 years and males by 15–20 compared to the
people without diabetes. The overall incidence of myocardial
infarction, stroke, and heart failure is about twofold in T2D
compared to the people without diabetes. The diabetes-
related excess risk of myocardial infarction is much higher
for women than for men, while for the other CVDs, people
with T2D of the two sexes have a similar excess risk. In
light of finding possible mechanisms to explain the partial
loss of advantage for myocardial infarction and not for the
other two types of events, we foresee a second study to inves-
tigate the determinants of CVD events only in population
with T2D using information about prescribed drug and on
other areas of care such as tests and lifestyle factors and
diabetes duration.
Ethical Approval
This is an observational study and the data were collected
retrospectively. The Local Health Authority of Reggio Emilia
was responsible for collecting and processing the data.
The REDR has been approved by the provincial Ethic
Committee on July 23rd, 2014. The aim of the study is consis-
tent with the specific objective of the REDR as approved by
the Ethic Committee. According to Italian privacy law, no
patient or parental consent is required for large retrospective
population-based studies approved by the competent Ethic
Committee, if data are published only in aggregated form.
Competing Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
The authors thank the Planning and Control Staff, Local
Health Authority of Reggio Emilia, and the Department of
Laboratory Medicine, IRCCS-Arcispedale Santa Maria
Nuova, Reggio Emilia, for providing the data for the register.
The study has been partially funded by Emilia-Romagna
region (dgr 798/2015).
References
[1] Global Burden of Disease Study 2013 Collaborators, “Global,
regional, and national incidence, prevalence, and years lived
with disability for 301 acute and chronic diseases and injuries
in 188 countries, 1990–2013: a systematic analysis for the
Global Burden of Disease Study 2013,” The Lancet, vol. 386,
no. 9995, pp. 743–800, 2015.
[2] M. Nichols, N. Townsend, P. Scarborough, and M. Rayner,
“Cardiovascular disease in Europe 2014: epidemiological
update,” European Heart Journal, vol. 35, no. 42, pp. 2950–
2959, 2014.
[3] NCD Risk Factor Collaboration (NCD-RisC), “Worldwide
trends in diabetes since 1980: a pooled analysis of 751
population-based studies with 4.4 million participants,” The
Lancet, vol. 387, no. 10027, pp. 1513–1530, 2016.
[4] American Diabetes Association, “8. Cardiovascular Disease
and Risk Management,” Diabetes Care, vol. 39, Supplement 1,
pp. S60–S71, 2016.
[5] T. Almdal, H. Scharling, J. S. Jensen, and H. Vestergaard, “The
independent effect of type 2 diabetes mellitus on ischemic
heart disease, stroke, and death: a population-based study
of 13,000 men and women with 20 years of follow-up,”
Archives of Internal Medicine, vol. 164, no. 13, pp. 1422–
1426, 2004.
[6] K. N. Barnett, S. A. Ogston, M. E. T. McMurdo, A. D. Morris,
and J. M. M. Evans, “A 12-year follow-up study of all-cause
and cardiovascular mortality among 10,532 people newly
diagnosed with Type 2 diabetes in Tayside, Scotland,” Diabetic
Medicine, vol. 27, no. 10, pp. 1124–1129, 2010.
[7] G. L. Booth, M. K. Kapral, K. Fung, and J. V Tu, “Relation
between age and cardiovascular disease inmenandwomenwith
diabetes compared with non-diabetic people: a population-
based retrospective cohort study,” The Lancet, vol. 368,
no. 9529, pp. 29–36, 2006.
[8] A. Cohen-Solal, F. Beauvais, and D. Logeart, “Heart failure
and diabetes mellitus: epidemiology and management of an
alarming association,” Journal of Cardiac Failure, vol. 14,
no. 7, pp. 615–625, 2008.
[9] G. A. Nichols, T. A. Hillier, J. R. Erbey, and J. B. Brown,
“Congestive heart failure in type 2 diabetes: prevalence,
incidence, and risk factors,” Diabetes Care, vol. 24, no. 9,
pp. 1614–1619, 2001.
[10] G. A. Nichols, C. M. Gullion, C. E. Koro, S. A. Ephross, and
J. B. Brown, “The incidence of congestive heart failure in
type 2 diabetes: an update,” Diabetes Care, vol. 27, no. 8,
pp. 1879–1884, 2004.
[11] A.Juutilainen,S.Kortelainen,S.Lehto,T.Rönnemaa,K.Pyörälä,
and M. Laakso, “Gender difference in the impact of type 2
diabetes on coronary heart disease risk,”Diabetes Care, vol. 27,
no. 12, pp. 2898–2904, 2004.
[12] S. R. Preis, S-J. Hwang, S. Coady et al., “Trends in all-cause
and cardiovascular disease mortality among women and
men with and without diabetes mellitus in the Framingham
Heart Study, 1950 to 2005,” Circulation, vol. 119, no. 13,
pp. 1728–1735, 2009.
[13] G. Hu, P. Jousilahti, Q. Qiao, S. Katoh, and J. Tuomilehto, “Sex
differences in cardiovascular and total mortality among
diabetic and non-diabetic individuals with or without
history of myocardial infarction,” Diabetologia, vol. 48, no. 5,
pp. 856–861, 2005.
[14] W. B. Kannel and P. W. Wilson, “Risk factors that attenuate
the female coronary disease advantage,” Archives of Internal
Medicine, vol. 155, no. 1, pp. 57–61, 1995.
[15] R. Huxley, F. Barzi, and M. Woodward, “Excess risk of
fatal coronary heart disease associated with diabetes in
men and women: meta-analysis of 37 prospective cohort
studies,” BMJ (Clinical Research Edition), vol. 332, no. 7533,
pp. 73–78, 2006.
7International Journal of Endocrinology
[16] P. Jousilahti, E. Vartiainen, J. Tuomilehto, and P. Puska,
“Sex, age, cardiovascular risk factors, and coronary heart
disease: a prospective follow-up study of 14 786 middle-aged
men and women in Finland,” Circulation, vol. 99, no. 9,
pp. 1165–1172, 1999.
[17] F. Mascarenhas-Melo, D. Marado, F. Palavra et al., “Diabetes
abrogates sex differences and aggravates cardiometabolic risk
in postmenopausal women,” Cardiovascular Diabetology,
vol. 12, 61 pages, 2013.
[18] M.Woodward, X. Zhang, F. Barzi et al., “The effects of diabetes
on the risks of major cardiovascular diseases and death in
the Asia-Pacific region,” Diabetes Care, vol. 26, no. 2,
pp. 360–366, 2003.
[19] I. Gouni-Berthold, H. K. Berthold, C. S. Mantzoros, M. Böhm,
and W. Krone, “Sex disparities in the treatment and control of
cardiovascular risk factors in type 2 diabetes,” Diabetes Care,
vol. 31, no. 7, pp. 1389–1391, 2008.
[20] S. A. E. Peters, R. R. Huxley, N. Sattar, andM.Woodward, “Sex
Differences in the Excess Risk of Cardiovascular Diseases
Associated with Type 2 Diabetes: Potential Explanations and
Clinical Implications,” Current Cardiovascular Risk Reports,
vol. 9, no. 7, 36 pages, 2015.
[21] M. C. Rossi, M. R. Cristofaro, S. Gentile et al., “Sex disparities
in the quality of diabetes care: biological and cultural factors
may play a different role for different outcomes: a cross-
sectional observational study from the AMDAnnals initiative,”
Diabetes Care, vol. 36, no. 10, pp. 3162–3168, 2013.
[22] E. Barrett-Connor and D. L. Wingard, “Sex differential in
ischemic heart disease mortality in diabetics: a prospective
population-based study,” American Journal of Epidemiology,
vol. 118, no. 4, pp. 489–496, 1983.
[23] E. L. Barrett-Connor, B. A. Cohn, D. L. Wingard, and S. L.
Edelstein, “Why is diabetes mellitus a stronger risk factor for
fatal ischemic heart disease in women than in men? The
Rancho Bernardo Study,” JAMA: The Journal of the American
Medical Association, vol. 265, no. 5, pp. 627–631, 1991.
[24] S. Heyden, G. Heiss, A. G. Bartel, and C. G. Hames, “Sex
differences in coronary mortality among diabetics in Evans
County, Georgia,” Journal of Chronic Diseases, vol. 33, no. 5,
pp. 265–273, 1980.
[25] W. B. Kannel andD. L.McGee, “Diabetes and glucose tolerance
as risk factors for cardiovascular disease: the Framingham
study,”Diabetes Care, vol. 2, no. 2, pp. 120–126, 1979.
[26] M. Ogita, K. Miyauchi, T. Dohi et al., “Gender-based outcomes
among patients with diabetes mellitus after percutaneous cor-
onary intervention in the drug-eluting stent era,” International
Heart Journal, vol. 52, no. 6, pp. 348–352, 2011.
[27] D. S. H. Bell, “Heart failure: the frequent, forgotten, and often
fatal complication of diabetes,” Diabetes Care, vol. 26, no. 8,
pp. 2433–2441, 2003.
[28] J. G. Regensteiner, S. Golden, A. G. Huebschmann et al., “Sex
differences in the cardiovascular consequences of diabetes
mellitus: a scientific statement from the American Heart
Association,”Circulation, vol. 132, no. 25, pp. 2424–2447, 2015.
[29] P.Ballotari, S.ChiatamoneRanieri,M.Vicentini et al., “Building
a population-based diabetes register: an Italian experience,”
Diabetes Research and Clinical Practice, vol. 103, no. 1,
pp. 79–87, 2014.
[30] ISTAT, Resident Population on December 31st, 2011,
http://www.demo.istat.it/bil20111009/index.html.
[31] P. Ballotari, S. C. Ranieri, F. Luberto et al., “Sex differences in
cardiovascular mortality in diabetics and nondiabetic subjects:
a population-based study (Italy),” International Journal of
Endocrinology, vol. 2015, Article ID 914057, 10 pages, 2015.
[32] L. Policardo, G. Seghieri, P. Francesconi, R. Anichini,
F. Franconi, and S. Del Prato, “Gender difference in diabetes
related excess risk of cardiovascular events: When does the
‘risk window’ open?” Journal of Diabetes and Its Complications,
no. 16, pp. 30622–30625, 2016.
[33] E. W. Gregg, Q. Gu, Y. J. Cheng, K. M. V. Narayan, and C. C.
Cowie, “Mortality trends in men and women with diabetes,
1971 to 2000,” Annals of Internal Medicine, vol. 147, no. 3,
pp. 149–155, 2007.
[34] H. Liang, C. Vallarino, G. Joseph, S. Manne, A. Perez, and
S. Zhang, “Increased risk of subsequent myocardial infarction
in patients with type 2 diabetes: a retrospective cohort study
using the U.K. General Practice Research Database,” Diabetes
Care, vol. 37, no. 5, pp. 1329–1337, 2014.
[35] S. Yusuf, S. Hawken, S. Ounpuu et al., “Effect of potentially
modifiable risk factors associated with myocardial infarction
in 52 countries (the INTERHEART study): case–control
study,” The Lancet, vol. 364, no. 9438, pp. 937–952, 2004.
[36] S. A. E. Peters, R. R. Huxley, and M. Woodward, “Diabetes as
risk factor for incident coronary heart disease in women com-
pared with men: a systematic review and meta-analysis of 64
cohorts including 858,507 individuals and 28,203 coronary
events,”Diabetologia, vol. 57, no. 8, pp. 1542–1551, 2014.
[37] I. S. Thrainsdottir, T. Aspelund, G. Thorgeirsson et al., “The
association between glucose abnormalities and heart failure
in the population-based Reykjavik study,” Diabetes Care,
vol. 28, no. 3, pp. 612–616, 2005.
[38] R. Cui, H. Iso, K. Yamagishi et al., “Diabetesmellitus and risk of
stroke and its subtypes among Japanese: the Japan public
health center study,” Stroke, vol. 42, no. 9, pp. 2611–2614, 2011.
[39] N. Sarwar, P. Gao, S. R. K. Seshasai et al., “Diabetes mellitus,
fasting blood glucose concentration, and risk of vascular dis-
ease: a collaborative meta-analysis of 102 prospective studies,”
The Lancet, vol. 375, no. 9733, pp. 2215–2222, 2010.
[40] Y.Tanizaki,Y.Kiyohara, I.Katoetal.,“Incidenceandrisk factors
for subtypes of cerebral infarction in a general population: the
Hisayama study,” Stroke, vol. 31, no. 11, pp. 2616–2622, 2000.
[41] Y. Doi, T. Ninomiya, J. Hata et al., “Impact of glucose tolerance
status on development of ischemic stroke and coronary heart
disease in a general Japanese population: the Hisayama study,”
Stroke, vol. 41, no. 2, pp. 203–209, 2010.
[42] M. Hyvärinen, J. Tuomilehto, T. Laatikainen et al., “The
impact of diabetes on coronary heart disease differs from that
on ischaemic stroke with regard to the gender,” Cardiovascular
Diabetology, vol. 8, 17 pages, 2009.
[43] D. Giralt, S. Domingues-Montanari, M. Mendioroz et al., “The
gender gap in stroke: a meta-analysis,” Acta Neurologica
Scandinavica, vol. 125, no. 2, pp. 83–90, 2012.
[44] A. Kautzky-Willer, J. Harreiter, and G. Pacini, “Sex and
Gender Differences in Risk, Pathophysiology and Complica-
tions of Type 2 Diabetes Mellitus,” Endocrine Reviews, vol. 37,
no. 3, pp. 278–316, 2016.
[45] G. T. Russo, B. Pintaudi, C. Giorda et al., “Age- and
gender-related differences in LDL-cholesterol management in
outpatientswith type 2diabetesmellitus,” International Journal
of Endocrinology, vol. 2015, Article ID 957105, 8 pages, 2015.
8 International Journal of Endocrinology
[46] H. U. Krämer, E. Raum, G. Rüter et al., “Gender disparities in
diabetes and coronary heart disease medication among
patients with type 2 diabetes: results from the DIANA study,”
Cardiovascular Diabetology, vol. 11, 88 pages, 2012.
[47] D. J. Wexler, R. W. Grant, J. B. Meigs, D. M. Nathan, and
E. Cagliero, “Sex disparities in treatment of cardiac risk
factors in patients with type 2 diabetes,” Diabetes Care,
vol. 28, no. 3, pp. 514–520, 2005.
[48] R. Bugiardini, A. T. Yan, R. T. Yan et al., “Factors influencing
underutilization of evidence-based therapies in women,”
European Heart Journal, vol. 32, no. 11, pp. 1337–1344, 2011.
[49] L. Franzini, D. Ardigò, F. Cavalot et al., “Women show worse
control of type 2 diabetes and cardiovascular disease risk
factors than men: results from the MIND.IT Study Group of
the Italian Society of Diabetology,” Nutrition, Metabolism,
and Cardiovascular Diseases, vol. 23, no. 3, pp. 235–241, 2013.
9International Journal of Endocrinology
Submit your manuscripts at
https://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
